Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CYCyclacel Pharmaceuticals, Inc. logo

Cyclacel Pharmaceuticals, Inc. (CYCC)

NASDAQ Capital Market · Currency in USD
$6.37 ▼ -0.41 (-5.98%)
At close: Sep 11, 4:00 PM ET. Market closed.
$6.44 ▲ +0.08 (+1.18%)
After hours: Sep 11, 7:56 PM ET

Summary

Previous Close
$6.77
Open
$6.76
Day's Range
$6.10 – $6.96
52 Week Range
$3.08 – $597.60
Volume
219,909
Avg. Volume
1,812,692
Market Cap
$10.61M
Beta (5Y Monthly)
0.16
PE Ratio (TTM)
--
EPS (TTM)
-$0.32
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$1.00

Profile: Cyclacel Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
12
CEO
Sing Ee Wong

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical studies for solid tumors and is also being evaluated in combination with venetoclax for patients with chronic lymphocytic leukemia that has recurred or is resistant to previous therapies. CYC140, a polo-like kinase inhibitor, has progressed to Phase 1/2 clinical trials for the treatment of both advanced leukemias and solid malignancies.

Earnings

DateEst.Actual
Nov 13, 2025-$72.00-$0.00Beat
Aug 13, 2025-$72.00-$0.98Beat
May 15, 2025-$69.60-$6.25Beat
Nov 12, 2024-$129.54-$43.18Beat
Aug 14, 2024-$0.01-$1.73Miss
May 14, 2024-$0.05-$5.45Miss

Analyst view

Consensus price target
$1.00 ▼ -84.3%
Range $1.00 – $1.00
Rating: Buy
Buy 71% · Hold 29% · Sell 0%

Get free alerts on CYCC and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.